Delgocitinib Patent Status and Details
The patent application WO2017006968A1 relates to delgocitinib, a Janus kinase (JAK) inhibitor. This application was filed by Anacor Pharmaceuticals, Inc. and covers methods of treating autoimmune diseases [1].
What is Delgocitinib?
Delgocitinib is an orally administered pan-JAK inhibitor developed for the treatment of autoimmune diseases [1]. It is designed to modulate the immune system by blocking the activity of JAK enzymes, which play a role in inflammatory signaling pathways [1].
What does patent WO2017006968A1 cover?
Patent application WO2017006968A1 specifically claims methods for treating conditions such as psoriasis, atopic dermatitis, rheumatoid arthritis, and other immune-mediated inflammatory diseases using delgocitinib [1].
When does patent protection for delgocitinib expire?
The expiration of patent protection for delgocitinib will depend on the specific patents granted from applications like WO2017006968A1 and any extensions that may be available. Information on patent expiry dates for specific drugs can be found on resources like DrugPatentWatch.com [2].
Who is developing Delgocitinib?
Anacor Pharmaceuticals, Inc. originally filed patent application WO2017006968A1. Subsequent development and commercialization efforts for delgocitinib have been pursued by other entities, including AbbVie [3].
What are the clinical applications of Delgocitinib?
Delgocitinib is being investigated for its efficacy in treating various autoimmune and inflammatory conditions. Clinical trials have explored its use in patients with atopic dermatitis, rheumatoid arthritis, and other conditions where immune dysregulation contributes to disease progression [1][3].
How does Delgocitinib work?
Delgocitinib functions by inhibiting Janus kinases (JAKs). JAKs are intracellular enzymes that transmit signals from cytokine and growth factor receptors on the cell membrane to the nucleus, influencing gene expression related to inflammation and immunity. By blocking these pathways, delgocitinib aims to reduce the inflammatory processes characteristic of autoimmune diseases [1].
What is the status of Delgocitinib in regulatory review?
The regulatory status of delgocitinib varies by region and indication. For instance, delgocitinib has received approval in Japan for the treatment of atopic dermatitis under the brand name Coreact [3]. Further regulatory submissions and reviews are ongoing for other indications and in different geographical markets.
What are the risks associated with JAK inhibitors like Delgocitinib?
As with other JAK inhibitors, potential risks associated with delgocitinib include an increased risk of serious infections, cardiovascular events, thrombosis, and certain malignancies. These risks are carefully monitored during clinical development and post-market surveillance [3].
Sources:
[1] https://patents.google.com/patent/WO2017006968A1/
[2] https://drugpatentwatch.com/
[3] https://www.biospace.com/article/releases/anacor-pharmaceuticals- Announces-positive-top-line-results-from-phase-2b-study-of-an2728-delgocitinib-for-the-treatment-of-atopic-dermatitis-/